GlassScriptPhysician profile
John F Modlin
NPI 1538275334
$56,826.50
in general payments reported to CMS, 2019-2025
4 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what a typical Pediatric Infectious Diseases provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,864 · 2021: $29K · 2022: $5,704 · 2023: $12K · 2024: $5,864 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,800.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28,160.50 | 2021-2025 | Gardasil 9 |
| Pfizer INC. | $14,344.00 | 2019-2024 | |
| Sanofi Pasteur INC. | $9,072.00 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $5,250.00 | 2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Modlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.